sotalol has been researched along with Pregnancy in 49 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of sotalol in the treatment of fetal tachycardia." | 7.72 | Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, FF; Visser, GH, 2003) |
| "The authors envisage the hypothesis of an embryofetal intoxication by a beta-blocker (B-), sotalol, taken by the mother, not hypertensive, during all her pregnancy (160 mg/day)." | 7.67 | [Possible embryofetopathy caused by beta-blocker (sotalol) taken throughout the pregnancy]. ( Babin, JP; Carre, M; Martin, C, 1985) |
| " The elimination half-life after oral administration (about 10 h) and bioavailability (about 90%) were not altered significantly by pregnancy." | 6.65 | Pharmacokinetics of sotalol during pregnancy. ( Leahey, W; McDevitt, DG; Murnaghan, GA; O'Hare, MF, 1983) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 5.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| "We performed a systematic review and meta-analysis to compare digoxin, flecainide, or sotalol as first-line therapy for fetal tachycardia." | 4.95 | Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis. ( Frommelt, MA; Hill, GD; Kovach, JR; Saudek, DE; Singh, AK; Wehrheim, K, 2017) |
| " In the case of atrial flutters the pregnant woman is treated with sotalol administered orally and, if no sinus rhythm is obtained nor a reduced ventricular rhythm occurs, subsequently with digoxin." | 4.81 | [Protocols for the treatment of supraventricular tachycardias in the fetus]. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Stoutenbeek, P, 2001) |
| "Sotalol is a beta-adrenoceptor blocking agent devoid of intrinsic sympathomimetic activity, membrane stabilising actions and cardioselectivity." | 3.76 | Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. ( Deedwania, P; Nademanee, K; Singh, BN; Sorkin, EM; Ward, A, 1987) |
| "The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of sotalol in the treatment of fetal tachycardia." | 3.72 | Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, FF; Visser, GH, 2003) |
| "Comparative studies of drug effects in the adult and fetal rat were performed using three experimental models: (1) effects of almokalant upon pregnancy and fetal mortality in rats given daily doses of 0, 10, 50, 100, or 400 mumol." | 3.69 | Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. ( Abrahamsson, C; Bäärnhielm, C; Carlsson, L; Danielsson, B; Duker, G; Ljung, B; Palmer, M, 1994) |
| "Increased motor activity and poor performance in the active avoidance test were observed in the offspring of rats treated with dl-propranolol or sotalol during pregnancy, but not with atenolol and d-propranolol." | 3.68 | Behavioral and biochemical studies in rats following prenatal treatment with beta-adrenoceptor antagonists. ( Gitter, S; Gordon, I; Rehavi, M; Speiser, Z, 1991) |
| "The authors envisage the hypothesis of an embryofetal intoxication by a beta-blocker (B-), sotalol, taken by the mother, not hypertensive, during all her pregnancy (160 mg/day)." | 3.67 | [Possible embryofetopathy caused by beta-blocker (sotalol) taken throughout the pregnancy]. ( Babin, JP; Carre, M; Martin, C, 1985) |
| "The authors report two cases of fetal tachycardia treated in utero by digitalis (Digoxin) and a beta-blocker (Sotalol)." | 3.67 | [In utero treatment of fetal tachycardias with a digitalis-beta blocker combination. Apropos of 2 cases]. ( Auzelle, MP; Badoual, J; Boccara, JF; Caldera, R; Chavinie, J; Lachassine, E; Mensire, A, 1987) |
| "Neonatal tachyarrhythmia was observed in 31." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy." | 2.82 | Arrhythmias in Pregnancy. ( Briller, JE; Elkayam, U; Lakkireddy, DR; Mason, PK; Merchant, FM; Patel, H; Pillarisetti, J; Russo, AM; Tamirisa, KP; Vaseghi, M; Volgman, AS, 2022) |
| "Fetal hydrops was seen in 20 patients; 17 received maternal therapy, 2 were delivered and 1 was not treated because it had a severe nontreatable cardiac malformation." | 2.69 | Atrial flutter in the perinatal age group: diagnosis, management and outcome. ( Benatar, AA; Brenner, JI; Kleinman, CS; Lisowski, LA; Meijboom, EJ; Soyeur, DJ; Stoutenbeek, P; Verheijen, PM, 2000) |
| "The pharmacological treatment of fetal tachycardia (FT) has been described in various publications." | 2.41 | Drug treatment of fetal tachycardias. ( Ambachtsheer, BE; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, TF; Visser, GH, 2002) |
| " Investigators have hoped that these drugs would be as effective as sotalol and amiodarone but have fewer adverse effects." | 2.40 | The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. ( MacNeil, DJ, 1997) |
| "Sotalol is a class III antiarrhythmic that prolongs the action potential and refractoriness of cardiac tissue and has potent nonselective beta-blocking activity." | 2.38 | Sotalol: a new class III antiarrhythmic agent. ( Zanetti, LA, 1993) |
| "Fetal arrhythmias are common, and they may resolve spontaneously in majority of the cases." | 1.56 | Fetal arrhythmias: diagnosis and treatment. ( Yuan, SM, 2020) |
| "Fetal hydrops was present in six patients (five with SVT, one with AF)." | 1.39 | Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. ( Freund, MW; Manten, GT; Oudijk, MA; Pistorius, L; ter Heide, H; van der Heijden, LB, 2013) |
| "Sotalol was associated with higher rates of prenatal AF termination than digoxin (HR=5." | 1.37 | Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. ( Api, O; Blom, NA; Carvalho, JS; Clur, SA; De Groot, E; Jaeggi, ET; Manlhiot, C; McCrindle, BW; Rammeloo, L; Ryan, G, 2011) |
| "Digoxin therapy was initiated and sotalol was later added for new-onset hydrops." | 1.35 | Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report. ( Gonzalez, JM; Merriman, JB; Rychik, J; Ural, SH, 2008) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 1.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| "Supraventricular tachycardia is the most common clinically significant fetal tachycardia." | 1.32 | Fetal supraventricular tachycardia diagnosed and treated at twenty-four weeks of gestation and after birth: a case report. ( Annunziata, A; Calabrò, R; Cardaropoli, D; D'Alto, M; Pacileo, G; Paladini, D; Romeo, E; Russo, MG; Sarubbi, B, 2004) |
| "Hydrops fetalis was present in 9 fetuses." | 1.31 | Sotalol in the treatment of fetal dysrhythmias. ( Kapusta, L; Kleinman, CS; Meijboom, EJ; Michon, MM; Oudijk, MA; Stoutenbeek, P; Visser, GH, 2000) |
| "Sotalol is a beta-adrenoceptor blocking drug which also has class III antiarrhythmic properties via Ikr channel blockade." | 1.31 | Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol. ( Danielsson, BR; Sköld, AC, 2001) |
| "Sotalol was given orally to the mothers in a dose of 80-160 mg x 2." | 1.30 | Foetal supraventricular tachycardia treated with sotalol. ( Fouron, JC; Jaeggi, E; Sonesson, SE; Wesslen-Eriksson, E; Winberg, P, 1998) |
| " Dosing on gestational day (GD) 11 was associated with right-sided oblique cleft lip and short tail, while dosing on day 13 caused digital hypoplasia and/or amputation." | 1.29 | Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. ( Brown-Woodman, PD; Danielsson, BR; Snow, MD; Webster, WS, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (24.49) | 18.7374 |
| 1990's | 10 (20.41) | 18.2507 |
| 2000's | 12 (24.49) | 29.6817 |
| 2010's | 10 (20.41) | 24.3611 |
| 2020's | 5 (10.20) | 2.80 |
| Authors | Studies |
|---|---|
| Tamirisa, KP | 1 |
| Elkayam, U | 1 |
| Briller, JE | 1 |
| Mason, PK | 1 |
| Pillarisetti, J | 1 |
| Merchant, FM | 1 |
| Patel, H | 1 |
| Lakkireddy, DR | 1 |
| Russo, AM | 1 |
| Volgman, AS | 1 |
| Vaseghi, M | 1 |
| Miyoshi, T | 2 |
| Maeno, Y | 2 |
| Hamasaki, T | 2 |
| Inamura, N | 2 |
| Yasukochi, S | 2 |
| Kawataki, M | 2 |
| Horigome, H | 2 |
| Yoda, H | 2 |
| Taketazu, M | 2 |
| Nii, M | 2 |
| Hagiwara, A | 2 |
| Kato, H | 2 |
| Shimizu, W | 2 |
| Shiraishi, I | 2 |
| Sakaguchi, H | 2 |
| Ueda, K | 2 |
| Katsuragi, S | 2 |
| Yamamoto, H | 2 |
| Sago, H | 2 |
| Ikeda, T | 2 |
| Refaat, M | 1 |
| El Dick, J | 1 |
| Sabra, M | 1 |
| Bitar, F | 1 |
| Tayeh, C | 1 |
| Abutaqa, M | 1 |
| Arabi, M | 1 |
| Sonesson, SE | 2 |
| Acharya, G | 1 |
| Bjeloševič, M | 1 |
| Illíková, V | 1 |
| Tomko, J | 1 |
| Olejník, P | 1 |
| Chalupka, M | 1 |
| Hatala, R | 1 |
| Hill, GD | 1 |
| Kovach, JR | 1 |
| Saudek, DE | 1 |
| Singh, AK | 1 |
| Wehrheim, K | 1 |
| Frommelt, MA | 1 |
| Shozu, M | 1 |
| Bravo-Valenzuela, NJ | 1 |
| Peixoto, AB | 1 |
| Araujo Júnior, E | 1 |
| Tonni, G | 1 |
| Yuan, SM | 1 |
| Strasburger, JF | 1 |
| Ito, S | 1 |
| Stout, KK | 1 |
| Robinson, MR | 1 |
| Merriman, JB | 1 |
| Gonzalez, JM | 1 |
| Rychik, J | 1 |
| Ural, SH | 1 |
| Cuneo, BF | 1 |
| Suri, V | 1 |
| Keepanaseril, A | 1 |
| Aggarwal, N | 1 |
| Vijayvergiya, R | 1 |
| Jaeggi, ET | 1 |
| Carvalho, JS | 1 |
| De Groot, E | 1 |
| Api, O | 1 |
| Clur, SA | 1 |
| Rammeloo, L | 1 |
| McCrindle, BW | 1 |
| Ryan, G | 1 |
| Manlhiot, C | 1 |
| Blom, NA | 1 |
| Ishikawa, K | 1 |
| Kikuchi, A | 1 |
| Matsui, H | 1 |
| Tamaru, S | 1 |
| Imada, S | 1 |
| Horikoshi, T | 1 |
| Takagi, K | 1 |
| Shah, A | 1 |
| Moon-Grady, A | 1 |
| Bhogal, N | 1 |
| Collins, KK | 1 |
| Tacy, T | 1 |
| Brook, M | 1 |
| Hornberger, LK | 1 |
| van der Heijden, LB | 1 |
| Oudijk, MA | 5 |
| Manten, GT | 1 |
| ter Heide, H | 1 |
| Pistorius, L | 1 |
| Freund, MW | 1 |
| Jouannic, JM | 1 |
| Delahaye, S | 1 |
| Le Bidois, J | 1 |
| Fermont, L | 1 |
| Villain, E | 1 |
| Dommergues, M | 1 |
| Dumez, Y | 1 |
| Ruskamp, JM | 2 |
| Ververs, FF | 1 |
| Ambachtsheer, EB | 2 |
| Stoutenbeek, P | 5 |
| Visser, GH | 3 |
| Meijboom, EJ | 5 |
| Romeo, E | 1 |
| D'Alto, M | 1 |
| Russo, MG | 1 |
| Sarubbi, B | 1 |
| Cardaropoli, D | 1 |
| Paladini, D | 1 |
| Pacileo, G | 1 |
| Annunziata, A | 1 |
| Calabrò, R | 1 |
| Wu, TH | 1 |
| Huang, LC | 1 |
| Ho, M | 1 |
| Lee, CC | 1 |
| Chiu, TH | 1 |
| Hung, YC | 1 |
| Vandeputte-Van Messom, G | 1 |
| Burvenich, C | 1 |
| Peeters, G | 1 |
| O'Hare, MF | 3 |
| Leahey, W | 1 |
| Murnaghan, GA | 3 |
| McDevitt, DG | 3 |
| Erkkola, R | 1 |
| Lammintausta, R | 1 |
| Liukko, P | 1 |
| Anttila, M | 1 |
| Russell, CJ | 2 |
| Leahey, WJ | 2 |
| Varma, MP | 2 |
| Zanetti, LA | 1 |
| Abrahamsson, C | 1 |
| Palmer, M | 1 |
| Ljung, B | 1 |
| Duker, G | 1 |
| Bäärnhielm, C | 1 |
| Carlsson, L | 1 |
| Danielsson, B | 1 |
| Dunnington, CS | 1 |
| Pearce, SH | 1 |
| Rees, CJ | 1 |
| Smith, RH | 1 |
| Webster, WS | 1 |
| Brown-Woodman, PD | 1 |
| Snow, MD | 1 |
| Danielsson, BR | 2 |
| MacNeil, DJ | 1 |
| Fouron, JC | 1 |
| Wesslen-Eriksson, E | 1 |
| Jaeggi, E | 1 |
| Winberg, P | 1 |
| Lisowski, LA | 1 |
| Verheijen, PM | 1 |
| Benatar, AA | 1 |
| Soyeur, DJ | 1 |
| Brenner, JI | 1 |
| Kleinman, CS | 2 |
| Michon, MM | 1 |
| Kapusta, L | 1 |
| Sköld, AC | 1 |
| Ambachtsheer, BE | 1 |
| Ververs, TF | 1 |
| Van Petten, GR | 2 |
| Mears, GJ | 1 |
| Mathison, HJ | 1 |
| Speiser, Z | 1 |
| Gordon, I | 1 |
| Rehavi, M | 1 |
| Gitter, S | 1 |
| Wagner, X | 1 |
| Jouglard, J | 1 |
| Moulin, M | 1 |
| Miller, AM | 1 |
| Petitjean, J | 1 |
| Pisapia, A | 1 |
| Hackett, LP | 1 |
| Wojnar-Horton, RE | 1 |
| Dusci, LJ | 1 |
| Ilett, KF | 1 |
| Roberts, MJ | 1 |
| Babin, JP | 1 |
| Carre, M | 1 |
| Martin, C | 1 |
| Riant, P | 1 |
| Urien, S | 1 |
| Albengres, E | 1 |
| Duche, JC | 1 |
| Tillement, JP | 1 |
| Tanaka, H | 1 |
| Kasuya, Y | 1 |
| Saito, H | 1 |
| Shigenobu, K | 1 |
| Singh, BN | 1 |
| Deedwania, P | 1 |
| Nademanee, K | 1 |
| Ward, A | 1 |
| Sorkin, EM | 1 |
| Auzelle, MP | 1 |
| Mensire, A | 1 |
| Lachassine, E | 1 |
| Caldera, R | 1 |
| Boccara, JF | 1 |
| Chavinie, J | 1 |
| Badoual, J | 1 |
| Truelove, JF | 1 |
| Willes, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for sotalol and Pregnancy
| Article | Year |
|---|---|
Arrhythmias in Pregnancy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Pregnancy; Sotalol; Tachyca | 2022 |
Sotalol as an effective adjunct therapy in the management of supraventricular tachycardia induced fetal hydrops fetalis.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Fetal Diseases; Flecainid | 2020 |
Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis.
Topics: Anti-Arrhythmia Agents; Digoxin; Female; Fetal Diseases; Fetal Therapies; Flecainide; Humans; Pregna | 2017 |
Prenatal management with digoxin and sotalol combination for fetal supraventricular tachycardia: case report and review of literature.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Humans; Hydrops Fetalis; | 2009 |
Sotalol: a new class III antiarrhythmic agent.
Topics: Adult; Anti-Arrhythmia Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Interacti | 1993 |
Sotalol hydrochloride (Betapace): a new antiarrhythmic drug.
Topics: Adult; Angina Pectoris; Child; Clinical Protocols; Drug Interactions; Electrophysiology; Female; Hem | 1993 |
The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Conduction System; Heart Failur | 1997 |
[Protocols for the treatment of supraventricular tachycardias in the fetus].
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Drug Therapy, Combination; Fema | 2001 |
Drug treatment of fetal tachycardias.
Topics: Anti-Arrhythmia Agents; Clinical Trials as Topic; Digoxin; Female; Fetal Distress; Humans; Pregnancy | 2002 |
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Topics: Adult; Aged; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Pregnancy; | 1987 |
4 trials available for sotalol and Pregnancy
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Pharmacokinetics of sotalol during pregnancy.
Topics: Administration, Oral; Adult; Biological Availability; Female; Humans; Infusions, Parenteral; Kinetic | 1983 |
Atrial flutter in the perinatal age group: diagnosis, management and outcome.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Echocardiography, Doppler; Electric Countershock; E | 2000 |
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Topics: Adult; Aged; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Pregnancy; | 1987 |
36 other studies available for sotalol and Pregnancy
| Article | Year |
|---|---|
How to differentiate second-degree atrioventricular block from extrasystoles in fetuses with a bigeminal ventricular rhythm.
Topics: Atrioventricular Block; Cardiac Complexes, Premature; Digoxin; Female; Fetus; Flecainide; Humans; Pr | 2020 |
Supraventricular tachyarrhythmias during the intrauterine, neonatal, and infant period: A 10-year population-based study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Incidence; Infant; Infant, Newborn; Male; Pregna | 2020 |
Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Child Development; Child, Preschool; Digoxin; Drug Therapy, | 2017 |
Fetal supraventricular tachycardia at 12 weeks of gestation: diagnosis and follow up. A case report.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Echocardiography; Female; Fetal Heart; Follow-Up Studies; Hu | 2019 |
Fetal arrhythmias: diagnosis and treatment.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Digoxin; Female; Humans; Hydrops Fetalis; Pregnancy; S | 2020 |
Re: Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. L. B. van der Heijden, M. A. Oudijk, G. Manten, H. ter Heide, L. Pistorius and M. W. Freund. Ultrasound Obstet Gynecol 2013; 42: 285-293.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Female; Fetal Diseases; Humans; Pregnancy; Sotalol; Tachycar | 2013 |
Non-sustained ventricular tachycardia in a pregnant woman with repaired Tetralogy of Fallot: A challenging case.
Topics: Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Humans; | 2016 |
Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report.
Topics: Adolescent; Anti-Arrhythmia Agents; Digoxin; Female; Fetal Therapies; Humans; Hydrops Fetalis; Pregn | 2008 |
Treatment of fetal tachycardia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Electrophysiology; Digoxin; Female; Fetal Diseases; Huma | 2008 |
Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study.
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Evaluation; Female; Fetal Diseases; Fetal Therapies; Flecainid | 2011 |
Transplacental fetal therapy for junctional ectopic tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Electrocardiography; Female; Humans; Pregnancy; Pregnancy Ou | 2012 |
Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias.
Topics: Abortion, Induced; Anti-Arrhythmia Agents; Atrial Flutter; Bradycardia; Catheter Ablation; Digoxin; | 2012 |
Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Echocardiography; Female; Fetal Diseases; Follow-Up Studies; | 2013 |
[Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Echocardiography; F | 2003 |
Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics.
Topics: Amniotic Fluid; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Female; Fetal Blood; Fetal | 2003 |
Fetal supraventricular tachycardia diagnosed and treated at twenty-four weeks of gestation and after birth: a case report.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Female; Fetal Distress; Flecainide; Gestational Age; Humans; | 2004 |
Fetal atrial flutter: a case report and experience of sotalol treatment.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Delivery, | 2006 |
Action of epinephrine on the function of the teat sphincter in the lactating cow.
Topics: Animals; Cattle; Drug Interactions; Epinephrine; Female; Injections, Intra-Arterial; Lactation; Mamm | 1984 |
Transfer of propranolol and sotalol across the human placenta. Their effect on maternal and fetal plasma renin activity.
Topics: Adult; Female; Fetal Blood; Humans; Infant, Newborn; Maternal-Fetal Exchange; Placenta; Pregnancy; P | 1982 |
Sotalol as a hypotensive agent in pregnancy.
Topics: Adolescent; Adult; Amniotic Fluid; Female; Fetal Blood; Humans; Hypertension; Maternal-Fetal Exchang | 1980 |
Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Culture Techniques; Female; Fet | 1994 |
Fetal monitoring during maternal antiarrhythmic therapy.
Topics: Adenosine; Adult; Atenolol; Cardiotocography; Drug Therapy, Combination; Female; Humans; Infant, New | 1993 |
Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Arrhythmia Agents; Cleft Palate; Dose-Response Relationsh | 1996 |
Foetal supraventricular tachycardia treated with sotalol.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Fetal Diseases; Gestational Age; Humans | 1998 |
Sotalol in the treatment of fetal dysrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Hydrops Fetalis; Inf | 2000 |
Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Area Under Curve; Embryo Loss; Embryonic and Fetal Development; Fem | 2001 |
Sotalol in the management of hypertension complicating pregnancy [proceedings].
Topics: Female; Humans; Hypertension; Pregnancy; Pregnancy Complications, Cardiovascular; Sotalol | 1979 |
Transfer of beta blocking drugs from the amniotic fluid to the fetal and maternal circulation.
Topics: Amniotic Fluid; Animals; Female; Fetal Heart; Fetus; Gestational Age; Heart Rate; Isoproterenol; Mat | 1978 |
Behavioral and biochemical studies in rats following prenatal treatment with beta-adrenoceptor antagonists.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Atenolol; Avoidance Le | 1991 |
Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk.
Topics: Adult; Cardiac Complexes, Premature; Drug Therapy, Combination; Female; Flecainide; Humans; Maternal | 1990 |
Excretion of sotalol in breast milk.
Topics: Adult; Arrhythmias, Cardiac; Cardiomyopathies; Female; Humans; Infant, Newborn; Milk, Human; Pregnan | 1990 |
[Possible embryofetopathy caused by beta-blocker (sotalol) taken throughout the pregnancy].
Topics: Abnormalities, Drug-Induced; Adult; Bradycardia; Cardiac Complexes, Premature; Facial Bones; Female; | 1985 |
High plasma protein binding as a parameter in the selection of betablockers for lactating women.
Topics: Acebutolol; Adrenergic beta-Antagonists; Blood Proteins; Female; Humans; Hypertension; Lactation; Mi | 1986 |
Organ culture of rat heart: maintained high sensitivity of fetal atria before innervation to norepinephrine.
Topics: Animals; Animals, Newborn; Colforsin; Culture Media; Electrophysiology; Female; Fetus; Heart; Heart | 1988 |
[In utero treatment of fetal tachycardias with a digitalis-beta blocker combination. Apropos of 2 cases].
Topics: Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Fetal Diseases; Humans; Pregnancy; | 1987 |
Action of several -adrenoceptor blocking drugs in the pregnant sheep and foetus.
Topics: Acetals; Adrenergic beta-Antagonists; Amino Alcohols; Animals; Ethanolamines; Female; Fetus; Heart R | 1973 |